|
Press Releases |
|
 |
|
Thursday, July 29, 2021 |
|
Eisai Listed for 20th Consecutive Year in FTSE4Good Index Series, An Index for Socially Responsible Investment |
Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 20th consecutive year since its initial inclusion in 2002. more info >> |
|
Tuesday, July 27, 2021 |
|
Biogen and Eisai Announce ADUHELM (aducanumab-avwa) Data Presentations at Alzheimer's Association International Conference 2021 |
Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen, as part of its Alzheimer's disease (AD) research portfolio, will contribute four virtual posters that showcase data from its clinical trials with ADUHELMTM (aducanumab-avwa) injection 100 mg/mL solution at the AAIC. more info >> |
|
Friday, July 23, 2021 |
|
Eisai: FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma |
Study Results Demonstrated Statistically Significant Improvements in Overall Survival, Progression-Free Survival and Overall Response Rate, Helping to Address a Significant Unmet Need in Advanced Endometrial Carcinoma. more info >> |
|
Wednesday, July 21, 2021 |
|
Eisai to Present Latest Data on Pipeline Assets in The Area of Alzheimer's Disease and Dementia at AAIC 2021 |
Eisai Co., Ltd. announced today that the company will conduct a total of 11 presentations, including the latest data of the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (development code: BAN2401) for which the U.S. Food and Drug Administration has granted Breakthrough Therapy designation, at the Alzheimer's Association International Conference (AAIC). more info >> |
|
Monday, July 19, 2021 |
|
Eisai Launchs Bile Acid Transporter Inhibitor Goofice in Thailand |
Eisai Co., Ltd. announced that its Thailand subsidiary Eisai (Thailand) Marketing Co., Ltd. has launched the bile acid transporter inhibitor Goofice (generic name: elobixibat hydrate) in Thailand. more info >> |
|
Thursday, July 1, 2021 |
|
Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong |
Eisai Co., Ltd. announced today that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has launched the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. more info >> |
|
Thursday, June 24, 2021 |
|
Eisai and Biogen Inc. Announce U.S. FDA Grants Breakthough Therapy Designation for Lecanemab (BAN2401) |
Eisai Co., Ltd. and Biogen Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthough Therapy designation for lecanemab (BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of Alzheimer's disease (AD). more info >> |
|
Wednesday, June 23, 2021 |
|
Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Approved In Japan For EZH2 Gene Mutation-positive Follicular Lymphoma |
Eisai Co., Ltd. announced today that it has obtained manufacturing and marketing approval for the EZH2 inhibitor "Tazverik Tablets 200 mg" (tazemetostat hydrobromide) in Japan with the indication of relapsed or refractory EZH2 gene mutation-positive follicular lymphoma (only when standard treatment is not applicable). more info >> |
|
Friday, June 18, 2021 |
|
Eisai, Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai's MORAb-202 Antibody Drug Conjugate |
Eisai Co., Ltd. and Bristol-Myers Squibb Company announced today that the companies have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC). more info >> |
|
Tuesday, June 15, 2021 |
|
Eisai to Divest Rights for Zonegran in Europe and Other Regions to Advanz Pharma |
Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for the antiepileptic agent Zonegran (generic name: zonisamide) in Europe, the Middle East, Russia, and Australia to Advanz Pharma. more info >> |
|
|
|
|
|
|
|
|
 |
Latest Press Releases |
 |
Mitsubishi Motors Added to FTSE4Good Index Series, FTSE Blossom Japan Index and FTSE Blossom Japan Sector Relative Index for Consecutive Years
Jul 11, 2025 16:28 JST
|
|
|
Bluemount Holdings Limited Announces Pricing of $5.5 Million Initial Public Offering
Jul 11, 2025 08:28 HKT/SGT
|
|
|
ZA Miner Launches AI-Powered Bitcoin Mining Contracts, Marking Milestone in Cloud Mining Innovation
Jul 11, 2025 07:00 HKT/SGT
|
|
|
XDS Datacentres and ICS Arabia partner to launch landmark 10MW Immersive Cooling Data Center in KSA
Jul 11, 2025 06:00 HKT/SGT
|
|
|
Alpaca Network Announces Launch of Modelz: The First Decentralized Exchange for AI Models
Jul 10, 2025 23:00 HKT/SGT
|
|
|
All-New MAZDA CX-5 Debuts in Europe
Jul 10, 2025 18:56 JST
|
|
|
Sharp Signs Official Partnership with Tottenham Hotspur FC Pre-season Tour 2025 with Its AQUOS Brand
Jul 10, 2025 17:30 JST
|
|
|
The 10th Quam IR Awards was Successfully Held
Jul 10, 2025 15:12 HKT/SGT
|
|
|
Tianci International: Discussing Strategic Opportunities for the Shipping and Logistics Industry to Integrate with Blockchain Technology and RWA
Jul 10, 2025 12:30 HKT/SGT
|
|
|
Tradable Bits Powers Fan Engagement for Rugby Australia's Hosting of the Qatar Airways British & Irish Lions Men's Tour 2025
Jul 10, 2025 07:30 HKT/SGT
|
|
|
Hola Prime Unveils 'Hola Prime Futures' with Industry-First 1-Hour Withdrawals, Expands Forex Offering with MT4 Integration
Jul 10, 2025 07:00 HKT/SGT
|
|
|
SAPPE's Female CEO Takes the World Stage at the Global Summit of Women 2025 in Berlin, Germany
Jul 9, 2025 22:00 HKT/SGT
|
|
|
Cornerstone Robotics Launches First Clinical Evaluation of its Hong Kong-Developed Surgical Robotic System in UK
Jul 9, 2025 20:32 HKT/SGT
|
|
|
Standard Chartered GBA Business Confidence Survey points to further tariff drag in H2
Jul 9, 2025 18:55 HKT/SGT
|
|
|
Hitachi develops "Metaverse Platform for Nuclear Power Plants" to enhance efficiency in construction and maintenance operations
Jul 9, 2025 19:02 JST
|
|
|
|
More Press release >> |
|
|
 |
 |
 |
|
|